Amgen Inc. closed 16.06% short of its 52-week high of $346.85, which the company reached on July 25th.

In a report released yesterday, Gregory Renza from RBC Capital maintained a Buy rating on Agios Pharma (AGIO – Research Report), with a price ...

In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on aTyr Pharma (ATYR – Research Report), with a price target ...

While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...

Amgen, Inc. ( NASDAQ: AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel ...

Amgen’s Blincyto (blinatumomab) has been approved by the European Commission (EC) to treat certain acute lymphoblastic leukaemia (ALL) patients earlier in their treatment journey. Blincyto monotherapy ...

Rua Dr. Diogo de Faria, 1087 – 9º andar – Vila Clementino 04037-003 São Paulo/SP - Brasil E-mail: [email protected] ...

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation ...

Many Americans support prohibiting commercials for prescription drugs on television. But enacting that ban could be complicated.

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME ...